1
|
Zhou Y, Ru Y, Shi H, Wang Y, Wu B, Upur H, Zhang Y. Cholecystokinin receptors regulate sperm protein tyrosine phosphorylation via uptake of HCO3-. Reproduction 2015; 150:257-68. [PMID: 26175429 DOI: 10.1530/rep-15-0138] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Accepted: 07/14/2015] [Indexed: 11/08/2022]
Abstract
Cholecystokinin (CCK), a peptide hormone and a neurotransmitter, was detected in mature sperm two decades ago. However, the exact role of CCK and the types of CCK receptors (now termed CCK1 and CCK2) in sperm have not been identified. Here, we find that CCK1 and CCK2 receptors are immunolocalized to the acrosomal region of mature sperm. The antagonist of CCK1 or CCK2 receptor strongly activated the soluble adenylyl cyclase/cAMP/protein kinase A signaling pathway that drives sperm capacitation-associated protein tyrosine phosphorylation in dose- and time-dependent manners. But these actions of stimulation were abolished when sperm were incubated in the medium in the absence of HCO3-. Further investigation demonstrated that the inhibitor of CCK1 or CCK2 receptor could accelerate the uptake of HCO3- and significantly elevate the intracellular pH of sperm. Interestingly, the synthetic octapeptide of CCK (CCK8) showed the same action and mechanism as antagonists of CCK receptors. Moreover, CCK8 and the antagonist of CCK1 or CCK2 receptor were also able to accelerate human sperm capacitation-associated protein tyrosine phosphorylation by stimulating the influx of HCO3-. Thus, the present results suggest that CCK and its receptors may regulate sperm capacitation-associated protein tyrosine phosphorylation by modulating the uptake of HCO3-.
Collapse
Affiliation(s)
- Yuchuan Zhou
- State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China
| | - Yanfei Ru
- State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China
| | - Huijuan Shi
- State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China
| | - Yanjiao Wang
- State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China
| | - Bin Wu
- State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China
| | - Halmurat Upur
- State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China
| | - Yonglian Zhang
- State Key Laboratory of Molecular BiologyShanghai Key Laboratory for Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, People's Republic of ChinaShanghai institute of Planned Parenthood ResearchShanghai, ChinaCollege of Basic MedicalXinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, Shanghai, China
| |
Collapse
|
2
|
Staljanssens D, De Vos WH, Willems P, Van Camp J, Smagghe G. Time-resolved quantitative analysis of CCK1 receptor-induced intracellular calcium increase. Peptides 2012; 34:219-25. [PMID: 21352882 DOI: 10.1016/j.peptides.2011.02.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2011] [Revised: 02/11/2011] [Accepted: 02/15/2011] [Indexed: 01/18/2023]
Abstract
Cholecystokinin (CCK) is a gastrointestinal hormone, which regulates many physiological functions such as satiety by binding to the CCK receptor (CCKR). Molecules, which recognize this receptor can mimic or block CCK signaling and thereby influence CCKR-mediated processes. We have set up a quantitative heterologous assay with CHO cells over-expressing the rat CCK1 receptor to screen for such candidate molecules. Receptor activation, induced by agonist binding, is followed by an intracellular calcium increase, which was monitored using a fluorescent sensor dye. For quantification of the calcium increase, a population average technique using a fluorescence plate reader was optimized and subsequently compared with a single-cell approach using confocal microscopy. With both strategies, dose-response curves were generated for the natural agonist CCK-8S, the partial agonist JMV-180 as well as the antagonist lorglumide. Significant differences were found between the ligands and a strong correspondence was observed between both methods in terms of maximum response and median effect concentrations. Both highly sensitive methods proved complementary: whereas the plate reader assay allowed faster, high throughput screening, the confocal microscopy identified single-cell variations and revealed factors that reduce specificity and sensitivity.
Collapse
|
4
|
Sabaté JM, Gorbatchef C, Flourié B, Jian R, Coffin B. Cholecystokinin octapeptide increases rectal sensitivity to pain in healthy subjects. Neurogastroenterol Motil 2002; 14:689-95. [PMID: 12464091 DOI: 10.1046/j.1365-2982.2002.00370.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Hypersensitivity during rectal distension has been demonstrated in irritable bowel syndrome (IBS). Studies performed in animals and indirect data in humans suggest that cholecystokinin (CCK) could modulate visceral sensations. The aim of this study was to assess the effects of i.v. infused sulphated cholecystokinin octapeptide (CCK-OP) on rectal sensitivity in response to distension. In eight healthy subjects, rectal sensitivity and compliance were determined during a randomized double-blind study, with four sessions each separated by 7 days. Sensory thresholds and rectal compliance were assessed during slow-ramp (40 mL min-1) and rapid-phasic distensions (40 mL s-1, 5 mmHg stepwise, 1-min duration), and were compared before and during continuous infusion of either saline or CCK-OP at 5, or 20 or 40 ng kg-1 h-1. During rapid phasic distension but not during slow ramp distension, CCK-OP at 40 ng kg-1 h-1 produced a significant decrease in sensory thresholds compared with the basal period. Rectal compliance was not modified by any infusion. At pharmacological doses, CCK-OP decreases sensory thresholds during rapid phasic distension that may preferentially stimulate serosal mechanoreceptors, but has no effect on mucosal mechanoreceptors stimulated during slow ramp distensions. Modulation of rectal sensitivity by CCK could be implicated in the pathogenesis of the rectal hypersensitivity observed in IBS.
Collapse
Affiliation(s)
- J-M Sabaté
- Gastroenterology Unit, AP-HP Hopital Louis Mourier, Colombes, France
| | | | | | | | | |
Collapse
|
5
|
Abstract
1. The peptide hormone and neurotransmitter, cholecystokinin, is widely distributed throughout the gastrointestinal tract and central nervous system and mediates a diverse number of biological functions. 2. Two receptor subtypes, CCK-A and CCK-B, have been identified by both pharmacological characterization and molecular cloning. The CCK-A receptor is the predominant peripheral CCK receptor subtype and the CCK-B receptor is the predominant central CCK receptor. In addition, there are discrete populations of CCK-A receptors in the brain and CCK-B receptors are present in gastric mucosa. 3. Subtype selective antagonists have been developed which discriminate between the two receptor subtypes. One of the major chemical classes has exploited a benzodiazepine template present in asperlicin which was initially discovered in a natural product screen for CCK receptor antagonists. 4. The structurally related benzodiazepines L-365,260, L-740,093, and YM022 are selective antagonists of the CCK-B receptor subtype. Their in vitro pharmacological profiles have been characterized using the human CCK-B receptor expressed in CHO cells. 5. L-365,260 behaves in a manner consistent with that of a competitive antagonist and both L-740,093 and YM022 behave as insurmountable CCK-B receptor antagonists in vitro.
Collapse
Affiliation(s)
- J Dunlop
- CNS Disorders, Wyeth-Ayerst Research, Princeton, NJ 08543, USA.
| |
Collapse
|
6
|
Dunlop J, Pass I, Ennis C. The cholecystokinin-B receptor antagonist L-740,093 produces an insurmountable antagonism of CCK-4 stimulated functional response in cells expressing the human CCK-B receptor. Neuropeptides 1998; 32:157-60. [PMID: 9639254 DOI: 10.1016/s0143-4179(98)90031-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
A stable cell line expressing the human cholecystokinin-B receptor gene (hCCK-B.CHO) has been employed in an evaluation of the recently developed CCK-B receptor antagonist L-740,093. L-740,093 exhibited high affinity (IC50 0.49 nM) and selectivity (<50% displacement at CCK-A sites at 1 microM) for the human CCK-B receptor subtype as estimated from [125I]-CCK-8S displacement studies with membranes prepared from hCCK-B.CHO cells. The elevation of intracellular free Ca2+ in hCCK-B.CHO cells in response to stimulation with CCK-4 was used to evaluate the antagonist activity of L-740,093 in vitro. L-740,093 potently (IC50 5.4 nM) antagonized the 30 nM CCK-4-stimulated Ca2+ mobilization in hCCK-B.CHO cells. Further studies were performed to investigate the nature of the antagonist activity of L-740,093. When tested at 10 nM L-740,093 produced a modest rightward shift in the CCK-4 dose response curve, an effect which was accompanied by a small reduction (13%) in the maximum response to CCK-4. In the presence of 30 nM L-740,093 the maximum functional response to CCK-4 was further reduced by 45% indicating that L-740,093 behaves as an insurmountable antagonist of the human CCK-B receptor subtype.
Collapse
Affiliation(s)
- J Dunlop
- Biochemistry Laboratory, Wyeth Research Ltd, Maidenhead, UK.
| | | | | |
Collapse
|